vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and Connect Biopharma Holdings Ltd (CNTB). Click either name above to swap in a different company.

California BanCorp \ CA is the larger business by last-quarter revenue ($45.9M vs $24.1M, roughly 1.9× Connect Biopharma Holdings Ltd). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs 35.8%, a 25.8% gap on every dollar of revenue.

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

BCAL vs CNTB — Head-to-Head

Bigger by revenue
BCAL
BCAL
1.9× larger
BCAL
$45.9M
$24.1M
CNTB
Higher net margin
CNTB
CNTB
25.8% more per $
CNTB
61.6%
35.8%
BCAL

Income Statement — Q4 FY2025 vs Q2 FY2024

Metric
BCAL
BCAL
CNTB
CNTB
Revenue
$45.9M
$24.1M
Net Profit
$16.4M
$14.8M
Gross Margin
Operating Margin
48.8%
56.6%
Net Margin
35.8%
61.6%
Revenue YoY
0.8%
Net Profit YoY
-2.1%
148.7%
EPS (diluted)
$0.50
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
CNTB
CNTB
Q4 25
$45.9M
Q3 25
$45.2M
Q2 25
$44.3M
Q1 25
$44.8M
Q4 24
$45.5M
Q3 24
$38.1M
Q2 24
$22.2M
$24.1M
Q1 24
$21.9M
Net Profit
BCAL
BCAL
CNTB
CNTB
Q4 25
$16.4M
Q3 25
$15.7M
Q2 25
$14.1M
Q1 25
$16.9M
Q4 24
$16.8M
Q3 24
$-16.5M
Q2 24
$190.0K
$14.8M
Q1 24
$4.9M
Operating Margin
BCAL
BCAL
CNTB
CNTB
Q4 25
48.8%
Q3 25
48.3%
Q2 25
45.3%
Q1 25
52.8%
Q4 24
52.2%
Q3 24
-59.1%
Q2 24
1.3%
56.6%
Q1 24
33.1%
Net Margin
BCAL
BCAL
CNTB
CNTB
Q4 25
35.8%
Q3 25
34.7%
Q2 25
31.8%
Q1 25
37.6%
Q4 24
37.7%
Q3 24
-43.2%
Q2 24
0.9%
61.6%
Q1 24
22.5%
EPS (diluted)
BCAL
BCAL
CNTB
CNTB
Q4 25
$0.50
Q3 25
$0.48
Q2 25
$0.43
Q1 25
$0.52
Q4 24
$0.54
Q3 24
$-0.59
Q2 24
$0.01
$0.27
Q1 24
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
CNTB
CNTB
Cash + ST InvestmentsLiquidity on hand
$399.9M
$110.2M
Total DebtLower is stronger
$33.8M
Stockholders' EquityBook value
$576.6M
$110.9M
Total Assets
$4.0B
$120.6M
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
CNTB
CNTB
Q4 25
$399.9M
Q3 25
$559.2M
Q2 25
$430.1M
Q1 25
$439.2M
Q4 24
$388.2M
Q3 24
$614.4M
Q2 24
$104.7M
$110.2M
Q1 24
$86.5M
Total Debt
BCAL
BCAL
CNTB
CNTB
Q4 25
$33.8M
Q3 25
$33.4M
Q2 25
$52.9M
Q1 25
$70.3M
Q4 24
$69.7M
Q3 24
$69.1M
Q2 24
$42.9M
Q1 24
$44.9M
Stockholders' Equity
BCAL
BCAL
CNTB
CNTB
Q4 25
$576.6M
Q3 25
$564.7M
Q2 25
$547.6M
Q1 25
$531.4M
Q4 24
$511.8M
Q3 24
$498.1M
Q2 24
$293.2M
$110.9M
Q1 24
$292.5M
Total Assets
BCAL
BCAL
CNTB
CNTB
Q4 25
$4.0B
Q3 25
$4.1B
Q2 25
$4.0B
Q1 25
$4.0B
Q4 24
$4.0B
Q3 24
$4.4B
Q2 24
$2.3B
$120.6M
Q1 24
$2.3B
Debt / Equity
BCAL
BCAL
CNTB
CNTB
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
CNTB
CNTB
Operating Cash FlowLast quarter
$57.3M
$-8.0M
Free Cash FlowOCF − Capex
$56.9M
FCF MarginFCF / Revenue
124.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
3.49×
-0.54×
TTM Free Cash FlowTrailing 4 quarters
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
CNTB
CNTB
Q4 25
$57.3M
Q3 25
$16.0M
Q2 25
$13.4M
Q1 25
$7.0M
Q4 24
$50.3M
Q3 24
$18.3M
Q2 24
$309.0K
$-8.0M
Q1 24
$8.1M
Free Cash Flow
BCAL
BCAL
CNTB
CNTB
Q4 25
$56.9M
Q3 25
$15.9M
Q2 25
$13.4M
Q1 25
$6.9M
Q4 24
$49.7M
Q3 24
$18.1M
Q2 24
$171.0K
Q1 24
$8.0M
FCF Margin
BCAL
BCAL
CNTB
CNTB
Q4 25
124.1%
Q3 25
35.1%
Q2 25
30.2%
Q1 25
15.3%
Q4 24
109.2%
Q3 24
47.5%
Q2 24
0.8%
Q1 24
36.4%
Capex Intensity
BCAL
BCAL
CNTB
CNTB
Q4 25
0.8%
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.2%
Q4 24
1.2%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.4%
Cash Conversion
BCAL
BCAL
CNTB
CNTB
Q4 25
3.49×
Q3 25
1.02×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
-0.54×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons